Phase Ib, Open-label, Multi-centre Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
The purpose of this study is to combine the PDR001 checkpoint inhibitor with each of four
agents with immunomodulatory activity to identify the doses and schedule for combination
therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical
activity of these combinations.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society